Hedge Fund Stock Picks & Ticker Coverage
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Artisan Mid Cap Fund Matt Kamm, Jason White, Jim Hamel, Angela Wu, Jay Warner | “Veracyte ($VCYT) is a specialized molecular diagnostics company developing advanced genomic assays that assist oncologists in accurately diagnosing complex cancers and avoiding unnecessary surgical interventions. While the manager remains fundamentally constructive on the company's long-term standing in precision oncology, they trimmed the position during the quarter due to near-term revenue headwinds in its prostate franchise. The commercial strength of Veracyte's testing suite rests on extensive clinical utility and proprietary genomic algorithms that create durable intellectual property barriers. Its high-margin, specialized testing model generates strong incremental unit margins once lab infrastructure is fully capitalized. However, revenue growth experienced friction as clinical treatment guideline modifications for low-risk prostate cancer patients weighed on test volumes for its core Decipher assay, temporarily damping the platform's operating leverage. Future catalysts center on the commercial ramp and broader payer reimbursement of the Prosigna breast cancer test, alongside clinical trial publications for early-stage diagnostic pipelines. Key risks encompass sustained volume deceleration in Decipher testing, shifts in medical society guidelines, and Medicare reimbursement rate pressures.” | BULL | Q3 2026 Oct 14, 2026 | View Pitch |
Meridian Small Cap Growth Fund Chad Meade | “Veracyte, Inc. (VCYT) is a profitable genomic diagnostics company anchored by its Decipher prostate cancer test and Afirma thyroid test, supported by a deep base of proprietary clinical evidence. We own it for its durable, volume-driven testing revenue, expanding menu, and a defensible competitive moat built over more than a decade of evidence generation. Shares advanced sharply during the quarter after a strong earnings beat and raised full-year guidance, underpinned by continued double-digit volume growth in Decipher and improved Afirma performance following a workflow upgrade that reduced its no-result rate. Two upcoming launches—Prosigna in breast cancer and the TrueMRD platform in bladder cancer—together with a steady cadence of clinical data, reinforced confidence in a multi-year growth runway.” | NEUTRAL | Q2 2026 Jul 28, 2026 | View Pitch |
Meridian Small Cap Growth Fund Chad Meade | “Veracyte is a cancer diagnostics developer whose shares dropped following news of potentially ending funding for its loss-making French subsidiary. The manager considers this headwind and minor pipeline delays highly manageable, especially given strong top- and bottom-line results and improving profitability. Consequently, the fund added to its position during the quarter.” | BULL | Q1 2025 Mar 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.